Table 2.
Top metabolites associated with gastric cancer risk, multivariable conditional logistic regression
| Metabolites | SUPER.PATHWAY | SUB.PATHWAY | OR (95%CI)a | Pb |
|---|---|---|---|---|
| orotate | Nucleotide | Pyrimidine Metabolism, Orotate containing | 1.71 (1.30–2.26) | 1.25×10−4 |
| 1-(1-enyl-palmitoyl)-GPE (P-16:0) | Lipid | Lysoplasmalogen | 1.56 (1.24–1.97) | 1.89×10−4 |
| sphinganine | Lipid | Sphingolipid Synthesis | 1.55 (1.23–1.95) | 1.92×10−4 |
| 1-(1-enyl-stearoyl)-GPE (P-18:0) | Lipid | Lysoplasmalogen | 1.55 (1.22–1.98) | 3.85×10−4 |
| glycerophosphoethanolamine | Lipid | Phospholipid Metabolism | 1.55 (1.21–2.00) | 5.95×10−4 |
| 5alpha-pregnan-3beta, 20beta-diol monosulfate | Lipid | Progestin Steroids | 1.45 (1.15–1.82) | 0.00157 |
| N6-methyllysine | Amino Acid | Lysine Metabolism | 1.40 (1.13–1.74) | 0.0023 |
| 3-hydroxypyridine sulfate | Xenobiotics | Chemical | 0.68 (0.53–0.87) | 0.00236 |
| 1-(1-enyl-oleoyl)-2-docosahexaenoyl-GPE (P-18:1/22:6) | Lipid | Plasmalogen | 1.42 (1.13–1.79) | 0.00254 |
| 1-palmitoyl-GPC (16:0) | Lipid | Lysophospholipid | 1.44 (1.13–1.82) | 0.00272 |
| 1-(1-enyl-palmitoyl)-GPC (P-16:0) | Lipid | Lysoplasmalogen | 1.40 (1.11–1.75) | 0.00378 |
| quinate | Xenobiotics | Food Component/Plant | 0.70 (0.55–0.89) | 0.00391 |
| 1-stearoyl-GPC (18:0) | Lipid | Lysophospholipid | 1.42 (1.12–1.79) | 0.00408 |
| methylmalonate (MMA) | Lipid | Fatty Acid Metabolism (also BCAA Metabolism) | 1.42 (1.12–1.80) | 0.00419 |
| N-(2-furoyl) glycine | Xenobiotics | Food Component/Plant | 0.70 (0.54–0.90) | 0.0047 |
| 5alpha-pregnan-diol disulfate | Lipid | Progestin Steroids | 1.39 (1.10–1.75) | 0.00638 |
| glutamate | Amino Acid | Glutamate Metabolism | 1.38 (1.09–1.74) | 0.00793 |
| cysteine | Amino Acid | Methionine, Cysteine, SAM and Taurine Metabolism | 0.73 (0.58–0.93) | 0.00893 |
a
Adjusted for time to last meal, measured glucose levels, BMI, ever smoking, income, HP infection status (based on Omp and HP 0305), gastritis, and family history of gastric cancer, in addition to matching variables (age [± 2 years], gender, date of sample collection [± 30 days], time of sample collection [morning or afternoon], recent antibiotic use [yes, no], and menopausal status [for SWHS]).
b
The top five associations had a FDR<0.1.